Baxdrostat (Baxfendy), a selective oral aldosterone synthase inhibitor, has received FDA approval in May 2026 for hypertension, according to the drug’s Phase 3 profile in the BaxHTN program. The molecule targets CYP11B2 with reported greater than 100-fold selectivity over CYP11B1, addressing a historical challenge in aldosterone synthase inhibitor development. In the completed Phase 3 trial, clinically meaningful blood pressure reductions were reported at low doses (1 mg and 2 mg once daily), meeting both primary and secondary endpoints that supported the approval. The approval expands the class toolkit for hypertension tied to aldosterone signaling. Clinically, the key watch points will be real-world tolerability, titration strategy, and how baxdrostat performs in patient subgroups with varying baseline renin-angiotensin-aldosterone axis activity.